Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?

Peter Dreger*, Johannes Schetelig, Niels Andersen, Paolo Corradini, Michel van Gelder, John Gribben, Eva Kimby, Mauricette Michallet, Carol Moreno, Stephan Stilgenbauer, Emili Montserrat

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

132 Citations (Web of Science)


Allogeneic hematopoietic stem cell transplantation (HSCT) has been considered as the treatment of choice for patients with high-risk chronic lymphocytic leukemia (HR-CLL; ie, refractory to purine analogs, short response [
Original languageEnglish
Pages (from-to)3841-3849
Issue number26
Publication statusPublished - 18 Dec 2014

Cite this